Summary | |
---|---|
Symbol | STARD13 |
Name | StAR-related lipid transfer (START) domain containing 13 |
Aliases | GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ...... |
Chromosomal Location | 13q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm. Membrane; Peripheral membrane protein; Cytoplasmic side. Mitochondrion membrane; Peripheral membrane protein; Cytoplasmic side. Lipid droplet. |
Domain |
PF00620 RhoGAP domain PF07647 SAM domain (Sterile alpha motif) PF01852 START domain |
Function |
GTPase-activating protein for RhoA, and perhaps for Cdc42. May be involved in regulation of cytoskeletal reorganization, cell proliferation and cell motility. Acts a tumor suppressor in hepatocellular carcinoma cells. |
Biological Process |
GO:0001525 angiogenesis GO:0001667 ameboidal-type cell migration GO:0002040 sprouting angiogenesis GO:0002042 cell migration involved in sprouting angiogenesis GO:0003158 endothelium development GO:0003159 morphogenesis of an endothelium GO:0010594 regulation of endothelial cell migration GO:0010596 negative regulation of endothelial cell migration GO:0010631 epithelial cell migration GO:0010632 regulation of epithelial cell migration GO:0010633 negative regulation of epithelial cell migration GO:0016525 negative regulation of angiogenesis GO:0030336 negative regulation of cell migration GO:0035239 tube morphogenesis GO:0040013 negative regulation of locomotion GO:0043534 blood vessel endothelial cell migration GO:0043535 regulation of blood vessel endothelial cell migration GO:0043537 negative regulation of blood vessel endothelial cell migration GO:0043542 endothelial cell migration GO:0045765 regulation of angiogenesis GO:0048514 blood vessel morphogenesis GO:0051056 regulation of small GTPase mediated signal transduction GO:0051271 negative regulation of cellular component movement GO:0060562 epithelial tube morphogenesis GO:0061154 endothelial tube morphogenesis GO:0090049 regulation of cell migration involved in sprouting angiogenesis GO:0090051 negative regulation of cell migration involved in sprouting angiogenesis GO:0090130 tissue migration GO:0090132 epithelium migration GO:0097498 endothelial tube lumen extension GO:1901342 regulation of vasculature development GO:1901343 negative regulation of vasculature development GO:1903670 regulation of sprouting angiogenesis GO:1903671 negative regulation of sprouting angiogenesis GO:2000146 negative regulation of cell motility GO:2000181 negative regulation of blood vessel morphogenesis |
Molecular Function |
GO:0005096 GTPase activator activity GO:0008047 enzyme activator activity GO:0030695 GTPase regulator activity GO:0060589 nucleoside-triphosphatase regulator activity |
Cellular Component |
GO:0005811 lipid particle |
KEGG | - |
Reactome |
R-HSA-194840: Rho GTPase cycle R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases |
Summary | |
---|---|
Symbol | STARD13 |
Name | StAR-related lipid transfer (START) domain containing 13 |
Aliases | GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ...... |
Chromosomal Location | 13q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between STARD13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | STARD13 |
Name | StAR-related lipid transfer (START) domain containing 13 |
Aliases | GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ...... |
Chromosomal Location | 13q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of STARD13 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | STARD13 |
Name | StAR-related lipid transfer (START) domain containing 13 |
Aliases | GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ...... |
Chromosomal Location | 13q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of STARD13 in various data sets.
|
Points in the above scatter plot represent the mutation difference of STARD13 in various data sets.
|
Summary | |
---|---|
Symbol | STARD13 |
Name | StAR-related lipid transfer (START) domain containing 13 |
Aliases | GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ...... |
Chromosomal Location | 13q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STARD13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | STARD13 |
Name | StAR-related lipid transfer (START) domain containing 13 |
Aliases | GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ...... |
Chromosomal Location | 13q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STARD13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STARD13. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | STARD13 |
Name | StAR-related lipid transfer (START) domain containing 13 |
Aliases | GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ...... |
Chromosomal Location | 13q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STARD13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | STARD13 |
Name | StAR-related lipid transfer (START) domain containing 13 |
Aliases | GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ...... |
Chromosomal Location | 13q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of STARD13 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | STARD13 |
Name | StAR-related lipid transfer (START) domain containing 13 |
Aliases | GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ...... |
Chromosomal Location | 13q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between STARD13 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | STARD13 |
Name | StAR-related lipid transfer (START) domain containing 13 |
Aliases | GT650; ARHGAP37; LINC00464; START domain containing 13; long intergenic non-protein coding RNA 464; Rho GTPa ...... |
Chromosomal Location | 13q13.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting STARD13 collected from DrugBank database. |
There is no record. |